Skip to content

Study · Case report or series · n = 1 · 2026

4 results

The Liraglutide-Induced Pemphigus Vulgaris: A First Case Report Highlighting Autoimmune Risks of GLP-1 Receptor Agonists.

Cai S, Zhang Z, Ding W, Zhou S, Qiu X, Hou F, Wu C, Shen Z, Feng X, Jiang L

Endocrine, metabolic & immune disorders drug targets1 Jan 2026Cited by 2 (Europe PMC)

PMID40264312 (opens in a new tab)DOI10.2174/0118715303361089250320050246 (opens in a new tab)PepBankPUB-40264312
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanCase report or seriesSafety outcome

    In a 40-year-old woman with type 2 diabetes, erosive oral lesions developed three months after starting liraglutide, and histopathology confirmed pemphigus vulgaris.

    In plain wordsIn one woman with type 2 diabetes, oral lesions developed three months after liraglutide and testing confirmed pemphigus vulgaris.

    Peptide
    Liraglutide
    Outcome
    Not applicablePemphigus vulgaris
    Study

    n = 1

    Outcome group
    Adverse events · Skin and wound
    Studied dose
    Dose not stated · 3 monthsAs given in this study (human).

    Source sentences

    Summary
    The patient developed erosive lesions on the palatal and buccal mucosa three months after initiating liraglutide therapy. Histopathological examination confirmed the diagnosis of PV.
    1 context sentence
    Summary · context
    We report the first case of liraglutide-induced PV in a 40-year-old female patient with type 2 diabetes mellitus.
  2. 02HumanCase report or seriesSafety outcome

    In a 40-year-old woman with type 2 diabetes, lesions recurred when liraglutide was reintroduced.

    In plain wordsIn one woman with type 2 diabetes, lesions returned when liraglutide was restarted.

    Peptide
    Liraglutide
    Outcome
    Not applicablePemphigus vulgaris recurrence on liraglutide reintroduction
    Study

    n = 1

    Outcome group
    Adverse events · Skin and wound
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The patient showed partial remission after liraglutide discontinuation and topical glucocorticoid therapy, but lesions recurred when liraglutide was reintroduced.
    1 context sentence
    Summary · context
    We report the first case of liraglutide-induced PV in a 40-year-old female patient with type 2 diabetes mellitus.

Studies that did not test the peptide alone2

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

  1. 03HumanNot a test of Liraglutide aloneCase report or seriesSafety outcome

    In a 40-year-old woman with type 2 diabetes, pemphigus vulgaris partially remitted after liraglutide discontinuation and topical glucocorticoid therapy.

    In plain wordsIn one woman with type 2 diabetes, pemphigus partly improved after liraglutide was stopped and topical glucocorticoid treatment was given.

    Peptide
    Liraglutide
    Outcome
    DecreasePartial remission after liraglutide discontinuation and topical glucocorticoid therapy
    Study

    n = 1

    Outcome group
    Adverse events · Skin and wound

    Source sentences

    Summary
    The patient showed partial remission after liraglutide discontinuation and topical glucocorticoid therapy, but lesions recurred when liraglutide was reintroduced.
    1 context sentence
    Summary · context
    We report the first case of liraglutide-induced PV in a 40-year-old female patient with type 2 diabetes mellitus.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  2. 04LabNot a test of Liraglutide aloneOther designOther

    In an in vitro gamma-interferon release assay, positive results supported the diagnosis of drug-induced pemphigus in the liraglutide case.

    In plain wordsIn a laboratory assay from this case, positive results supported the drug-induced pemphigus diagnosis.

    Peptide
    Liraglutide
    Outcome
    Not applicableIn vitro gamma-interferon release assay result
    Study

    humann: not reported in source

    in vitro gamma-interferon release assay
    Outcome group
    Immune response · Immune and inflammation

    Source sentences

    Summary
    The temporal association with liraglutide use, combined with positive results from in vitro gamma-interferon release assays, supports the diagnosis of DIP.
    1 context sentence
    Summary · context
    We report the first case of liraglutide-induced PV in a 40-year-old female patient with type 2 diabetes mellitus.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.